Printer Friendly

MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials.

MaxCyte Inc (LON: MXCT) CEO Doug Doerfler sat down with Proactive at the BIO Investor Forum in San Francisco.

Doerfler says the company is making 'exciting progress' with its early-stage cancer drug developed using its CARMA technology.

The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.

To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link:

COPYRIGHT 2019 NLA Access Media Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Proactive Investors United States
Date:Oct 25, 2019
Previous Article:NetCents Technology reports consistent growth in new merchant cryptocurrency signups.
Next Article:Nutritional High sign exclusive agreement with Golden Triangle Brands to U.S.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters